Options
» Caregivers
» Fight the Fight
» Items of Interest
» Prevention
» Research
» Treatment
» Weekly Videos

Ads




Enjoy Mediterranean Diet Food.  Free shipping on orders over $50

Newsletter
Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon
For
The Weekly Newsletter, just enter your email:




Research
  Print    Email 

Week of January 4 - January 10, 2008

Sugar
Sugar

CHICAGO --- A slow, chronic starvation of the brain as we age appears to be one of the major triggers of a biochemical process that causes some forms of Alzheimer's disease.

A new study from Northwestern University's Feinberg School of Medicine has found when the brain doesn't get enough sugar glucose -- as might occur when cardiovascular disease restricts the blood flow in arteries to the brain -- a process is launched that ultimately produces the sticky clumps of protein that appear to be a cause of Alzheimer's.

Robert Vassar, lead author, discovered a key brain protein is altered when the brain has a deficient supply of energy. The altered protein, called eIF2alpha, increases the production of an enzyme that, in turn, flips a switch to produce the sticky protein clumps. Vassar worked with human and mice brains in his research.

The study is published in the December 26 issue of the journal Neuron.

“This finding is significant because it suggests that improving blood flow to the brain might be an effective therapeutic approach to prevent or treat Alzheimer’s,” said Vassar, a professor of cell and molecular biology at the Feinberg School.

A simple preventive strategy people can follow to improve blood flow to the brain is getting exercise, reducing cholesterol and managing hypertension.

"If people start early enough, maybe they can dodge the bullet," Vassar said.  For people who already have symptoms, vasodilators, which increase blood flow, may help the delivery of oxygen and glucose to the brain, he added.

Vassar said it also is possible that drugs could be designed to block the eIF2alpha protein that begins the formation of the protein clumps, known as amyloid plaques.

An estimated 10 million baby boomers will develop Alzheimer's in their lifetime, according to the Alzheimer's Association. The disease usually begins after age 60, and risk rises with age. The direct and indirect cost of Alzheimer's and other dementias is about $148 billion a year.

The initial trigger of Alzheimer's has long been a mystery.

Ten years ago, it was Vassar who discovered the enzyme, BACE1, that was responsible for making the sticky clumps of protein that form outside neurons and disrupt their ability to send messages.

But the cause of the high levels of the protein in people with the disease has been unknown. Vassar’s study now shows that energy deprivation in the brain might be the trigger starting the process that forms plaques in Alzheimer’s. 

Vassar said his work suggests that Alzheimer’s disease may result from a less severe type of energy deprivation than occurs in a stroke.  Rather than dying, the brain cells react by increasing BACE1, which may be a protective response in the short term, but  harmful in the long term.

"A stroke is a blockage that prevents blood flow and produces cell death in an acute, dramatic event," Vassar said.  "What we are talking about here is a slow, insidious process over many years where people have a low level of cardiovascular disease or atherosclerosis in the brain. It's so mild, they don't even notice it, but it has an effect over time because it's producing a chronic reduction in the blood flow."

Vassar said when people reach a certain age, some may get increased levels of the enzymes that cause a build-up of the plaques. "Then they start falling off the cliff," he said.


MORE INFORMATION:

Vassar's research was funded by the National Institute on Aging, the MetLife Foundation and Northwestern University.

ARTICLES ON THIS SITE ON BRAIN-SUGAR DECLINE

Introducing Axona

Accera's Axona

Axona, for mild-to-moderate Alzheimer's, is a new FDA-regulated product to be released in the first quarter of 2009. It works by providing an alternative energy source to brain cells.


New Tests and Treatments Close in on Alzheimer's

Medicinal Milkshake

Milkshake-like medicine virtually halts Alzheimer's progression for 9-months, while blood-test may increase earliness of detection.

(Editor's Note: This article from 2007 refers to a medication called Ketasyn. Ketasyn is the former name of Axona.)


Doctors Should Heed Patients' Memory Complaints

SOURCES:

Northwestern University

Reviewed by Dr. Boaz Ancselovic, MD, Geriatrician, Alzheimer's Weekly

COPYRIGHT:

© 2008 Alzheimer's Weekly LLC. All Rights Reserved.



« Back
Most Read In This Section
Prana's Progress Inhibits Alzheimer's Damage

Reversal of Alzheimer’s Symptoms Within Minutes Reported in New Study

Progress on the "Oklahoma City Vaccination"

FDA-approved Gammagard Increases Antibodies That Clear Alzheimer's

Epix Trial Improved Alz Scores in Just Two Weeks

The "IDENTITY" Trial Enters Decisive Phase

14 Leading Researchers Explain Alzheimer's

Caprospinol Makes the List of the 6 Top Investigational Alzheimer's Drugs for 2008

Newsletter

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon  Weekly Newsletter
Just enter your Email:

Advertisement
Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon
Free Weekly Newsletter.
Just enter your email: